An Overview of Biotechnological Drug's Various Techniques of Downstream Process, Guideline's and Different Chromatographic Analysis
Abstract
Biotechnology, a field discovered in 1919, unites biology and engineering to harness living organisms for medical purposes. Fueled by using DNA's discovery in the 1950s, biotechnology has converted through genetic engineering, yielding impactful merchandise regulated by means of entities like the FDA. The manufacturing involves upstream and downstream processing including the various techniques involved in the downstream processing of biotechnological drugs, along with relevant guidelines and chromatographic analysis methods. The biotechnological industry, which integrates biological science with engineering, has significantly advanced since the discovery of DNA's structure, leading to the development of biopharmaceuticals. These drugs, including monoclonal antibodies, recombinant proteins, and gene therapies, are produced using living organisms and hold the potential for treating complex diseases. The downstream process, a crucial phase in biopharmaceutical production, involves the purification and formulation of drug products to meet stringent regulatory standards. Traditional techniques such as centrifugation, filtration, and chromatography are employed to extract and purify biopharmaceuticals. Chromatographic techniques, including ion exchange, affinity, and size exclusion chromatography, play a pivotal role in achieving the desired purity levels. However, these methods are often time-- consuming and expensive, necessitating continuous advancements in the field. The paper highlights the importance of regulatory guidelines, including cGMP, in ensuring the quality and safety of biopharmaceuticals. It also discusses the significant role of organizations such as the FDA and EMA in regulating biotechnological drug production. The evolution of downstream processing techniques and the development of novel methods promise greater efficiency, scalability, and cost-effectiveness in biopharmaceutical production. Understanding these advancements is essential for continued growth and innovation in the industry, ultimately contributing to improved patient care and pharmaceutical innovation.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Downstream processing accounts for 80% of production expenses, largely driven by the high cost of Protein A resin and virus filtration.
“Purification often exceeds the cost of upstream manufacturing, with downstream processing accounting for 80% of production expenses, largely driven by the high cost of Protein A resin and virus filtration [14, 23].”
From Current PAT Landscape in the Downstream Processing of Biopharmaceuticals (2025) · cites this paper as [14]
Cited by
Sorted by citations
Current PAT Landscape in the Downstream Processing of Biopharmaceuticals
Sathiyapriyan, P., Mukherjee, S., Vogel, T., Essen, L., Boerema, D., Vey, M., & Kalina, U. (2025) · Analytical Science Advances · doi:10.1002/ansa.70013 · Cited by 45 · see citing works
- Authors
- Demir, F., Albarri, R., & Unal, D. O.
- Affiliations
- Faculty of Pharmacy, Department of Analytical Chemistry, Institute of Health Science, Istanbul University, 34126, Beyazit, Istanbul, Turkey
- Faculty of Pharmacy, Department of Analytical Chemistry, Istanbul University, 34116, Beyazit, Istanbul, Turkey
- ORCID
- Demir, Filiz
- Venue
- Current Pharmaceutical Analysis
- Publisher
- Elsevier BV
- Published
- 2024-12
- Volume
- 20
- Issue
- 8
- Pages
- 729-742
- ISSN
- 1573-4129
- Cited by
- 3
- References
- 0
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review